Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.

Thomas H. Cartwright,Marwan Fakih,Pilar García-Alfonso,Zdeněk Linke,Ana Ruiz-Casado,Eduardo Polo Marqués,Pascaline Picard,Marina Celanovic,Arvind Rup Singh,Taylor Salinardi,Ian Chau

Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.

2020

Thomas H. Cartwright
Marwan Fakih
Pilar García-Alfonso
Zdeněk Linke
Ana Ruiz-Casado
Eduardo Polo Marqués
Pascaline Picard
Marina Celanovic
Arvind Rup Singh
Taylor Salinardi
Ian Chau

212Background: Anti-EGFR therapies are frequently given as first-line therapy for patients with mCRC, while anti-angiogenic therapies may be suitable at any line. Despite improving outcomes for pat...

Keywords:

post hoc
Growth factor receptor
FOLFIRI
Internal medicine
Colorectal cancer
Aflibercept
Medicine
Oncology
Pathology
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations